A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

HIV Infections Clinical Trial

Official title:

A Pilot Protocol to Determine the Effects of Chemical and Mechanical Stress on Rectal Permeability as a Surrogate for Toxicity Evaluation of Rectally Applied Microbicides

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00389311
• Other study ID #: CDC 200-2001-08015-02
• Status: Completed
• Phase: Phase 0
• First received: October 17, 2006
• Last updated: March 30, 2015
• Start date: April 2007
• Est. completion date: June 2009

Study information

• Verified date: January 2009
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if detectable changes in permeability of the lining of the colon are caused by either application of HIV microbicide gels or medical procedures, such as flexible sigmoidoscopy.

Description:

It is not currently known if procedures used to observe the lining of the distal colon, such as endoscopy with or without pinch biopsy, may cause mucosal trauma and thus alter colonic permeability. Additionally, the application of topical HIV microbicides (to prevent HIV transmission) and shearing forces associated with rectal intercourse might also adversely affect the epithelial layer, and thus alter colonic permeability. In order to appropriately interpret testing of the effects of topical HIV microbicides on the mucosal lining of the distal colon, it is essential to understand whether these procedures themselves, adversely affect the epithelial layer. If changes in permeability can be detected, this method may be developed to help determine microbicide distribution/toxicity in early phase studies, thus improving the selection of candidate microbicides for study in larger scale clinical trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: June 2009
• Est. primary completion date: February 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Greater than or equal to 21 years of age

• Prior history of receptive anal intercourse (RAI)

• Subjects must have a history of using commercially-available personal lubricants for RAI.

• Ability to provide signed informed consent.

• Willingness to abstain from lubricant use and anal receptive intercourse for 48 hours prior to and 48 hours after Phases A and B.

• Willingness to use a single dose of rectally-applied N-9.

Exclusion Criteria:

• Mental handicap or impaired cognitive performance status as judged by the investigator.

• Coagulation abnormality which would put the subject at risk for bleeding as judged by the Principal Investigator.

• History of anorectal surgery within the last month or the presence of any anorectal disease or condition that in the judgment of the investigator could affect permeability of the rectal mucosa.

• Presence of any painful anorectal conditions or anorectal lesions that would be tender to manipulation.

• History of occupational radiation exposure.

• History of acute or chronic diarrhea defined as three or more loose stools per day.

• History of any allergic response to rectal lubricants.

• History of sleep apnea, or airway problems with previous sedation procedures.

• History of significant adverse reaction to sedation medications.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Normosol-R

• Nonoxynol-9

Procedure:
• Gastrointestinal instrumentation

Locations

Country	Name	City	State
United States	The Johns Hopkins Hospital	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Fuchs EJ, Grohskopf LA, Lee LA, Bakshi RP, Hendrix CW. Quantitative assessment of altered rectal mucosal permeability due to rectally applied nonoxynol-9, biopsy, and simulated intercourse. J Infect Dis. 2013 May 1;207(9):1389-96. doi: 10.1093/infdis/jit0 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intra-subject comparison of urine and plasma concentrations of 99mTc-DTPA		0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours after introduction of the treatment assignment	Yes